This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer. 235 primary prostate cancer patients treated with ...

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not. “MPS2 could potentially improve the health of ...

After diagnosis, the participants went on to receive additional care and/or prostate cancer treatment: 25 (26.6%) were managed with active surveillance. 2 (2.1%) were treated with cryotherapy, which ...

Prostate cancer is a type of malignancy that arises in the prostate gland. Prostate cancer tends to develop in older men, aged 50 and over. In many cases prostate cancer develops slowly ...

It affects about 2% of the population and is mediated ... Alarming Rise in Rates of Advanced Prostate Cancer in California Feb. 3, 2025 — The incidence of advanced prostate cancer in California ...

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

Estimated numbers of new cancer cases and deaths in 2023 by cancer site and US state Current cancer incidence, mortality, and survival statistics Information on cancer symptoms, risk factors, early ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...